

# Joost Peter Schanstra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5970809/publications.pdf>

Version: 2024-02-01

180  
papers

8,812  
citations

38742

50  
h-index

53230

85  
g-index

188  
all docs

188  
docs citations

188  
times ranked

8838  
citing authors

#	ARTICLE	IF	CITATIONS
1	Definition, diagnosis and management of fetal lower urinary tract obstruction: consensus of the ERKNet CAKUT-Obstructive Uropathy Work Group. <i>Nature Reviews Urology</i> , 2022, 19, 295-303.	3.8	27
2	Collagen-Derived Peptides in CKD: A Link to Fibrosis. <i>Toxins</i> , 2022, 14, 10.	3.4	15
3	Haploinsufficiency of the mouse <i>Tshz3</i> gene leads to kidney defects. <i>Human Molecular Genetics</i> , 2022, 31, 1921-1945.	2.9	0
4	Amniotic fluid peptides predict postnatal kidney survival in developmental kidney disease. <i>Kidney International</i> , 2021, 99, 737-749.	5.2	15
5	Value of Urine Peptides in Assessing Kidney and Cardiovascular Disease. <i>Proteomics - Clinical Applications</i> , 2021, 15, e2000027.	1.6	29
6	PRYNT: a tool for prioritization of disease candidates from proteomics data using a combination of shortest-path and random walk algorithms. <i>Scientific Reports</i> , 2021, 11, 5764.	3.3	4
7	Urinary Peptides as Potential Non-Invasive Biomarkers for Lupus Nephritis: Results of the Peptidu-LUP Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1690.	2.4	10
8	Urinary peptides in heart failure: a link to molecular pathophysiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1875-1887.	7.1	37
9	Mapping of the amniotic fluid proteome of fetuses with congenital anomalies of the kidney and urinary tract identifies plastin 3 as a protein involved in glomerular integrity. <i>Journal of Pathology</i> , 2021, 254, 575-588.	4.5	4
10	Ibrutinib does not prevent kidney fibrosis following acute and chronic injury. <i>Scientific Reports</i> , 2021, 11, 11985.	3.3	1
11	Administration of the High-Density Lipoprotein Mimetic CER-001 for Inherited Lecithinâ€“Cholesterol Acyltransferase Deficiency. <i>Annals of Internal Medicine</i> , 2021, 174, 1022-1025.	3.9	13
12	Hepatocyte nuclear factorâ€“1 $\beta$ shapes the energetic homeostasis of kidney tubule cells. <i>FASEB Journal</i> , 2021, 35, e21931.	0.5	8
13	A single-center study to evaluate the efficacy of a fetal urine peptide signature predicting postnatal renal outcome in fetuses with posterior urethral valves. <i>Pediatric Nephrology</i> , 2020, 35, 469-475.	1.7	17
14	Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 827-836.	0.7	23
15	The ANTENATAL multicentre study to predict postnatal renal outcome in fetuses with posterior urethral valves: objectives and design. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 371-379.	2.9	18
16	The low affinity p75 neurotrophin receptor is down-regulated in congenital anomalies of the kidney and the urinary tract: Possible involvement in early nephrogenesis. <i>Biochemical and Biophysical Research Communications</i> , 2020, 533, 786-791.	2.1	3
17	Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer. <i>Diagnostics</i> , 2020, 10, 658.	2.6	7
18	Connectivity mapping of glomerular proteins identifies dimethylaminoparthenolide as a new inhibitor of diabetic kidney disease. <i>Scientific Reports</i> , 2020, 10, 14898.	3.3	14

#	ARTICLE	IF	CITATIONS
19	Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation. <i>Diagnostics</i> , 2020, 10, 655.	2.6	12
20	Comparison of the amniotic fluid and fetal urine peptidome for biomarker discovery in renal developmental disease. <i>Scientific Reports</i> , 2020, 10, 21706.	3.3	8
21	Associations of urinary polymeric immunoglobulin receptor peptides in the context of cardio-renal syndrome. <i>Scientific Reports</i> , 2020, 10, 8291.	3.3	10
22	The CKD plasma lipidome varies with disease severity and outcome. <i>Journal of Clinical Lipidology</i> , 2019, 13, 176-185.e8.	1.5	13
23	Apelin affects the mouse aging urinary peptidome with minimal effects on kidney. <i>Scientific Reports</i> , 2019, 9, 10647.	3.3	3
24	Proteomics based identification of KDM5 histone demethylases associated with cardiovascular disease. <i>EBioMedicine</i> , 2019, 41, 91-104.	6.1	23
25	Urinary proteome signature of Renal Cysts and Diabetes syndrome in children. <i>Scientific Reports</i> , 2019, 9, 2225.	3.3	15
26	Implementation of Proteomics Biomarkers in Nephrology: From Animal Models to Human Application?. <i>Proteomics - Clinical Applications</i> , 2019, 13, 1800089.	1.6	8
27	Risk profile, quality of life and care of patients with moderate and advanced CKD: The French CKD-REIN Cohort Study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 277-286.	0.7	49
28	Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment. <i>JCI Insight</i> , 2019, 4, .	5.0	25
29	Comparison of Urine and Plasma Peptidome Indicates Selectivity in Renal Peptide Handling. <i>Proteomics - Clinical Applications</i> , 2018, 12, e1700163.	1.6	38
30	Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease. <i>Journal of Translational Medicine</i> , 2018, 16, 104.	4.4	48
31	Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 438-447.e4.	2.3	20
32	Urinary peptidomics in kidney disease and drug research. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 259-268.	5.0	24
33	Combination of the fetal urinary metabolome and peptidome for the prediction of postnatal renal outcome in fetuses with PUV. <i>Journal of Proteomics</i> , 2018, 184, 1-9.	2.4	16
34	Ldlr and ApoE mice better mimic the human metabolite signature of increased carotid intima media thickness compared to other animal models of cardiovascular disease. <i>Atherosclerosis</i> , 2018, 276, 140-147.	0.8	13
35	A urinary proteome-based classifier for the early detection of decline in glomerular filtration. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw239.	0.7	73
36	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw337.	0.7	62

#	ARTICLE	IF	CITATIONS
37	Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. <i>Scientific Reports</i> , 2017, 7, 40473.	3.3	32
38	Systems biology combining human- and animal-data miRNA and mRNA data identifies new targets in ureteropelvic junction obstruction. <i>BMC Systems Biology</i> , 2017, 11, 31.	3.0	12
39	Increased urine acylcarnitines in diabetic ApoE <sup>-/-</sup> mice: Hydroxytetradecadienoylcarnitine (C14:2-OH) reflects diabetic nephropathy in a context of hyperlipidemia. <i>Biochemical and Biophysical Research Communications</i> , 2017, 487, 109-115.	2.1	21
40	Urinary lysophospholipids are increased in diabetic patients with nephropathy. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1103-1108.	2.3	24
41	Asymptomatic circulating T-cell clone cause renal polymorphic inflammatory fibrosis. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 781-786.	1.6	3
42	Hepatocyte Nuclear Factor-1 $\beta$ Controls Mitochondrial Respiration in Renal Tubular Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3205-3217.	6.1	43
43	Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. <i>Kidney International Reports</i> , 2017, 2, 1066-1075.	0.8	77
44	Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies?. <i>Scientific Reports</i> , 2017, 7, 16915.	3.3	67
45	Urinary peptidomics analysis reveals proteases involved in diabetic nephropathy. <i>Scientific Reports</i> , 2017, 7, 15160.	3.3	28
46	Lysophosphatidic Acid Protects Against Endotoxin-Induced Acute Kidney Injury. <i>Inflammation</i> , 2017, 40, 1707-1716.	3.8	20
47	The use of urinary proteomics in the assessment of suitability of mouse models for ageing. <i>PLoS ONE</i> , 2017, 12, e0166875.	2.5	17
48	Validity and reproducibility of a short food frequency questionnaire among patients with chronic kidney disease. <i>BMC Nephrology</i> , 2017, 18, 297.	1.8	19
49	Prediction of acute coronary syndromes by urinary proteome analysis. <i>PLoS ONE</i> , 2017, 12, e0172036.	2.5	30
50	Urinary Peptide Analysis Differentiates Pancreatic Cancer From Chronic Pancreatitis. <i>Pancreas</i> , 2016, 45, 1018-1026.	1.1	24
51	Calcineurin Inhibitors Downregulate HNF-1 $\beta$ and May Affect the Outcome of HNF1B Patients After Renal Transplantation. <i>Transplantation</i> , 2016, 100, 1970-1978.	1.0	6
52	Omics Tools for Exploration of Renal Disorders. , 2016, , 165-183.		0
53	A capillary electrophoresis coupled to mass spectrometry pipeline for long term comparable assessment of the urinary metabolome. <i>Scientific Reports</i> , 2016, 6, 34453.	3.3	28
54	Comparison of different statistical approaches for urinary peptide biomarker detection in the context of coronary artery disease. <i>BMC Bioinformatics</i> , 2016, 17, 496.	2.6	6

#	ARTICLE	IF	CITATIONS
55	Epidermal growth factor and kidney disease: a long-lasting story. <i>Kidney International</i> , 2016, 89, 985-987.	5.2	12
56	Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice. <i>Kidney International</i> , 2016, 90, 1045-1055.	5.2	31
57	Increased urinary lysophosphatidic acid in mouse with subtotal nephrectomy: potential involvement in chronic kidney disease. <i>Journal of Physiology and Biochemistry</i> , 2016, 72, 803-812.	3.0	18
58	Urinary biomarkers for renal tract malformations. <i>Expert Review of Proteomics</i> , 2016, 13, 1121-1129.	3.0	7
59	Addition to the Special Issue on the CTP network consisting of reviews and original papers emerging from the CTPIOD meeting (Contribution To Progress in Obesity and Diabetes Research) 2016. <i>Journal of Physiology and Biochemistry</i> , 2016, 73, 415-415.	3.0	0
60	Omics databases on kidney disease: where they can be found and how to benefit from them. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 343-352.	2.9	33
61	The role of urinary peptidomics in kidney disease research. <i>Kidney International</i> , 2016, 89, 539-545.	5.2	59
62	Proteomics of vitreous in neovascular age-related macular degeneration. <i>Experimental Eye Research</i> , 2016, 146, 107-117.	2.6	36
63	Proteomic Analysis of Vitreous Humor in Retinal Vein Occlusion. <i>PLoS ONE</i> , 2016, 11, e0158001.	2.5	21
64	Identification of Symptomatic Fetuses Infected with Cytomegalovirus Using Amniotic Fluid Peptide Biomarkers. <i>PLoS Pathogens</i> , 2016, 12, e1005395.	4.7	31
65	Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management. <i>Bioanalysis</i> , 2016, 8, 439-455.	1.5	11
66	Protein Interactome of Muscle Invasive Bladder Cancer. <i>PLoS ONE</i> , 2015, 10, e0116404.	2.5	12
67	Shear Stress-Induced Alteration of Epithelial Organization in Human Renal Tubular Cells. <i>PLoS ONE</i> , 2015, 10, e0131416.	2.5	54
68	Unmasking Silent Endothelial Activation in the Cardiovascular System Using Molecular Magnetic Resonance Imaging. <i>Theranostics</i> , 2015, 5, 1187-1202.	10.0	26
69	FP223 URINARY PEPTIDE-BASED PREDICTION OF PROGRESSION FROM CHRONIC KIDNEY DISEASE STAGE II TO III. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii141-iii141.	0.7	1
70	FP279 HIGH-RESOLUTION PLASMA PROTEOME ANALYSIS IDENTIFIES NEW CHANGES IN MOLECULAR MECHANISMS INVOLVED IN CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii160-iii161.	0.7	1
71	FP303 POSSIBLE ROLE OF MIRNAS IN OBSTRUCTIVE NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii168-iii168.	0.7	0
72	miRNAs in urine: a mirror image of kidney disease?. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 361-374.	3.1	30

#	ARTICLE	IF	CITATIONS
73	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1999-2010.	6.1	205
74	Pretransplant urinary proteome analysis does not predict development of chronic kidney disease after liver transplantation. <i>Liver International</i> , 2015, 35, 1893-1901.	3.9	6
75	New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1842-1852.	0.7	64
76	Kinin B1 receptor antagonism is equally efficient as angiotensin receptor 1 antagonism in reducing renal fibrosis in experimental obstructive nephropathy, but is not additive. <i>Frontiers in Pharmacology</i> , 2015, 6, 8.	3.5	9
77	Body fluid peptide and protein signatures in diabetic kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iv43-iv53.	0.7	7
78	FP308URINARY PROTEOMICS TO DECIPHER MOLECULAR PATHOPHYSIOLOGY OF CKD PROGRESSION. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii170-iii170.	0.7	0
79	Specific Macrophage Subtypes Influence the Progression of Rhabdomyolysis-Induced Kidney Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1363-1377.	6.1	122
80	Proteomic urinary biomarker approach in renal disease: from discovery to implementation. <i>Pediatric Nephrology</i> , 2015, 30, 713-725.	1.7	39
81	Identification of ageing-associated naturally occurring peptides in human urine. <i>Oncotarget</i> , 2015, 6, 34106-34117.	1.8	31
82	The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1500-1507.	0.7	81
83	Clinical proteomics in obstetrics and neonatology. <i>Expert Review of Proteomics</i> , 2014, 11, 75-89.	3.0	31
84	Label-free Quantitative Urinary Proteomics Identifies the Arginase Pathway as a New Player in Congenital Obstructive Nephropathy. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 3421-3434.	3.8	24
85	Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. <i>Journal of Proteomics</i> , 2014, 98, 44-58.	2.4	64
86	Proteome-Based Systems Biology Analysis of the Diabetic Mouse Aorta Reveals Major Changes in Fatty Acid Biosynthesis as Potential Hallmark in Diabetes Mellitus-Associated Vascular Disease. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 161-170.	5.1	22
87	Classical MALDI-MS versus CE-based ESI-MS proteomic profiling in urine for clinical applications. <i>Bioanalysis</i> , 2014, 6, 247-266.	1.5	20
88	Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases. <i>Expert Review of Proteomics</i> , 2014, 11, 535-548.	3.0	24
89	Proteome analysis in the assessment of ageing. <i>Ageing Research Reviews</i> , 2014, 18, 74-85.	10.9	18
90	The HNF1B score is a simple tool to select patients for HNF1B gene analysis. <i>Kidney International</i> , 2014, 86, 1007-1015.	5.2	104

#	ARTICLE	IF	CITATIONS
91	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1563-1570.	0.7	106
92	Proteomics of Vitreous Humor of Patients with Exudative Age-Related Macular Degeneration. <i>PLoS ONE</i> , 2014, 9, e96895.	2.5	74
93	The KUPNetViz: a biological network viewer for multiple -omics datasets in kidney diseases. <i>BMC Bioinformatics</i> , 2013, 14, 235.	2.6	13
94	Fetal Urinary Peptides to Predict Postnatal Outcome of Renal Disease in Fetuses with Posterior Urethral Valves (PUV). <i>Science Translational Medicine</i> , 2013, 5, 198ra106.	12.4	86
95	Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. <i>Proteomics</i> , 2013, 13, 2967-2975.	2.2	21
96	Dual effect of chemokine CCL7/MCP-3 in the development of renal tubulointerstitial fibrosis. <i>Biochemical and Biophysical Research Communications</i> , 2013, 438, 257-263.	2.1	20
97	Hnf-1 $\beta$ Transcription Factor Is an Early Hif-1 $\alpha$ -Independent Marker of Epithelial Hypoxia and Controls Renal Repair. <i>PLoS ONE</i> , 2013, 8, e63585.	2.5	23
98	Proteomics as a Quality Control Tool of Pharmaceutical Probiotic Bacterial Lysate Products. <i>PLoS ONE</i> , 2013, 8, e66682.	2.5	23
99	Long Term Metabolic Syndrome Induced by a High Fat High Fructose Diet Leads to Minimal Renal Injury in C57BL/6 Mice. <i>PLoS ONE</i> , 2013, 8, e76703.	2.5	50
100	Renal tubular fluid shear stress facilitates monocyte activation toward inflammatory macrophages. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, F1409-F1417.	2.7	18
101	The KUPKB: a novel Web application to access multiomics data on kidney disease. <i>FASEB Journal</i> , 2012, 26, 2145-2153.	0.5	33
102	A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases. <i>Journal of Proteomics</i> , 2012, 75, 5888-5897.	2.4	58
103	Urinary Proteome Analysis at 5-Year Followup of Patients With Nonoperated Ureteropelvic Junction Obstruction Suggests Ongoing Kidney Remodeling. <i>Journal of Urology</i> , 2012, 187, 1006-1011.	0.4	31
104	Populous: a tool for building OWL ontologies from templates. <i>BMC Bioinformatics</i> , 2012, 13, S5.	2.6	25
105	Implementation of proteomic biomarkers: making it work. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1027-1036.	3.4	151
106	Renal tubular fluid shear stress promotes endothelial cell activation. <i>Biochemical and Biophysical Research Communications</i> , 2011, 407, 813-817.	2.1	16
107	Congenital ureteropelvic junction obstruction: human disease and animal models. <i>International Journal of Experimental Pathology</i> , 2011, 92, 168-192.	1.3	81
108	Developing a kidney and urinary pathway knowledge base. <i>Journal of Biomedical Semantics</i> , 2011, 2, S7.	1.6	29

#	ARTICLE	IF	CITATIONS
109	CE-MS in biomarker discovery, validation, and clinical application. <i>Proteomics - Clinical Applications</i> , 2011, 5, 9-23.	1.6	88
110	Is the time ripe for kidney tissue proteomics?. <i>Proteomics - Clinical Applications</i> , 2011, 5, 215-221.	1.6	7
111	Renal and Urinary Proteomics. <i>Proteomics - Clinical Applications</i> , 2011, 5, 211-213.	1.6	3
112	Renal fibrosis: Insight from proteomics in animal models and human disease. <i>Proteomics</i> , 2011, 11, 805-815.	2.2	24
113	Pargyline reduces renal damage associated with ischaemia-reperfusion and cyclosporin. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 489-498.	0.7	24
114	Lysophosphatidic acid-1-receptor targeting agents for fibrosis. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 657-667.	4.1	72
115	Systems biology to battle vascular disease. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1019-1022.	0.7	22
116	Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease. <i>Pediatric Nephrology</i> , 2010, 25, 27-35.	1.7	66
117	Urinary proteome analysis identifies infants but not older children requiring pyeloplasty. <i>Pediatric Nephrology</i> , 2010, 25, 1673-1678.	1.7	58
118	Addressing the Challenge of Defining Valid Proteomic Biomarkers and Classifiers. <i>BMC Bioinformatics</i> , 2010, 11, 594.	2.6	108
119	Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. <i>Proteomics - Clinical Applications</i> , 2010, 4, 464-478.	1.6	139
120	Blockade of the Kinin B1 Receptor Ameliorates Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1157-1164.	6.1	47
121	Systems biology: opening new avenues in clinical research. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1015-1018.	0.7	36
122	Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 2424-2437.	3.8	434
123	Recommendations for Biomarker Identification and Qualification in Clinical Proteomics. <i>Science Translational Medicine</i> , 2010, 2, 46ps42.	12.4	273
124	Urinary Proteomics Based on Capillary Electrophoresis-Coupled Mass Spectrometry in Kidney Disease: Discovery and Validation of Biomarkers, and Clinical Application. <i>Advances in Chronic Kidney Disease</i> , 2010, 17, 493-506.	1.4	69
125	Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy. <i>FASEB Journal</i> , 2009, 23, 134-142.	0.5	60
126	Laminar Shear Stress Regulates Endothelial Kinin B1 Receptor Expression and Function. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1757-1763.	2.4	23



#	ARTICLE	IF	CITATIONS
127	Delayed Treatment with Plasminogen Activator Inhibitor-1 Decoys Reduces Tubulointerstitial Fibrosis. <i>Experimental Biology and Medicine</i> , 2009, 234, 1511-1518.	2.4	20
128	Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: An update of recent developments. <i>Mass Spectrometry Reviews</i> , 2009, 28, 703-724.	5.4	175
129	Capillary electrophoresis-mass spectrometry in urinary proteome analysis: current applications and future developments. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 393, 1431-1442.	3.7	41
130	The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. <i>Proteomics</i> , 2009, 9, 2108-2117.	2.2	82
131	2nd Combined Working Group and Management Committee Meeting of Urine and Kidney Proteomics COST Action 29-30 March 2009, Nafplio, Greece. <i>Proteomics - Clinical Applications</i> , 2009, 3, 1017-1022.	1.6	9
132	Molecular determinants of LPS-induced acute renal inflammation: Implication of the kinin B1 receptor. <i>Biochemical and Biophysical Research Communications</i> , 2009, 386, 407-412.	2.1	27
133	The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. <i>Proteomics - Clinical Applications</i> , 2008, 2, 997-1007.	1.6	64
134	CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. <i>Proteomics - Clinical Applications</i> , 2008, 2, 964-973.	1.6	178
135	Establishment of a European Network for Urine and Kidney Proteomics. <i>Journal of Proteomics</i> , 2008, 71, 490-492.	2.4	35
136	Lysophosphatidic acid and renal fibrosis. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2008, 1781, 582-587.	2.4	78
137	Urine in Clinical Proteomics. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 1850-1862.	3.8	368
138	Identification of Urinary Biomarkers by Proteomics in Newborns: Use in Obstructive Nephropathy. , 2008, 160, 127-141.		36
139	Kinin B1 Receptor Deficiency Leads to Leptin Hypersensitivity and Resistance to Obesity. <i>Diabetes</i> , 2008, 57, 1491-1500.	0.6	61
140	Role of Kinin B 2 Receptor Signaling in the Recruitment of Circulating Progenitor Cells With Neovascularization Potential. <i>Circulation Research</i> , 2008, 103, 1335-1343.	4.5	108
141	LPA1 Receptor Activation Promotes Renal Interstitial Fibrosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 3110-3118.	6.1	185
142	Gene expression profiling in the remnant kidney model of wild type and kinin B1 and B2 receptor knockout mice. <i>Kidney International</i> , 2007, 72, 442-454.	5.2	20
143	Anomalies of the TCF2 Gene Are the Main Cause of Fetal Bilateral Hyperechogenic Kidneys. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 923-933.	6.1	216
144	Participation of transmembrane proline 82 in angiotensin II AT1 receptor signal transduction. <i>Regulatory Peptides</i> , 2007, 140, 32-36.	1.9	13

#	ARTICLE	IF	CITATIONS
145	Functional rescue of a defective angiotensin II AT1 receptor mutant by the Mas protooncogene. <i>Regulatory Peptides</i> , 2007, 141, 159-167.	1.9	41
146	Body Fluid Proteomics for Biomarker Discovery: Lessons from the Past Hold the Key to Success in the Future. <i>Journal of Proteome Research</i> , 2007, 6, 4549-4555.	3.7	216
147	A nest in renal fibrosis?. <i>Kidney International</i> , 2007, 72, 242-244.	5.2	2
148	Clinical proteomics: A need to define the field and to begin to set adequate standards. <i>Proteomics - Clinical Applications</i> , 2007, 1, 148-156.	1.6	274
149	Non-invasive markers of ureteropelvic junction obstruction. <i>World Journal of Urology</i> , 2007, 25, 457-465.	2.2	49
150	Renal gene expression profiling using kinin B1 and B2 receptor knockout mice reveals comparable modulation of functionally related genes. <i>Biological Chemistry</i> , 2006, 387, 15-22.	2.5	11
151	Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. <i>Nature Medicine</i> , 2006, 12, 398-400.	30.7	248
152	Role of the kinin B1 receptor in insulin homeostasis and pancreatic islet function. <i>Biological Chemistry</i> , 2006, 387, 431-436.	2.5	34
153	Obstructive nephropathy: Insights from genetically engineered animals. <i>Kidney International</i> , 2005, 68, 925-937.	5.2	200
154	Expression and distribution of kinin B1 receptor in the rat brain and alterations induced by diabetes in the model of streptozotocin. <i>Synapse</i> , 2005, 57, 29-37.	1.2	22
155	Molecular structure and transcriptional regulation by nuclear factor- $\kappa$ B of the mouse kinin B1 receptor gene. <i>Biological Chemistry</i> , 2005, 386, 515-22.	2.5	8
156	Direct protein-protein interaction between PLC $\beta$ 1 and the bradykinin B2 receptor: Importance of growth conditions. <i>Biochemical and Biophysical Research Communications</i> , 2005, 326, 894-900.	2.1	11
157	Bradykinin and Renal Fibrosis: Have We ACE'd it?. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 2504-2506.	6.1	12
158	Decreased renal NO excretion and reduced glomerular tuft area in mice lacking the bradykinin B <sub>2</sub> receptor. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003, 284, H1904-H1908.	3.2	36
159	The protective effect of angiotensin converting enzyme inhibition in experimental renal fibrosis in mice is not mediated by bradykinin B2 receptor activation. <i>Thrombosis and Haemostasis</i> , 2003, 89, 735-40.	3.4	6
160	Induction of B <sub>1</sub> receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia-induced glomerular Erk 1 and 2 phosphorylation. <i>Canadian Journal of Physiology and Pharmacology</i> , 2002, 80, 328-333.	1.4	48
161	A Novel Protein-Protein Interaction between a G Protein-coupled Receptor and the Phosphatase SHP-2 Is Involved in Bradykinin-induced Inhibition of Cell Proliferation. <i>Journal of Biological Chemistry</i> , 2002, 277, 40375-40383.	3.4	59
162	Transcriptional Regulation of the Rat Bradykinin B2 Receptor Gene: Identification of a Silencer Element. <i>Molecular Pharmacology</i> , 2002, 62, 1344-1355.	2.3	17

#	ARTICLE	IF	CITATIONS
163	Induction of Functional Bradykinin B1-Receptors in Normotensive Rats and Mice Under Chronic Angiotensin-Converting Enzyme Inhibitor Treatment. <i>Circulation</i> , 2002, 105, 627-632.	1.6	115
164	B2receptor activation reduces Erk1 and Erk2 phosphorylation induced by insulin-like growth factor-1, platelet-derived growth factor-BB, and high glucose in rat isolated glomeruli. <i>Canadian Journal of Physiology and Pharmacology</i> , 2002, 80, 341-345.	1.4	4
165	Inhibition of IGF-1-induced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykinin. <i>Kidney International</i> , 2002, 62, 412-421.	5.2	27
166	In vivo bradykinin B2 receptor activation reduces renal fibrosis. <i>Journal of Clinical Investigation</i> , 2002, 110, 371-379.	8.2	123
167	In vivo bradykinin B2 receptor activation reduces renal fibrosis. <i>Journal of Clinical Investigation</i> , 2002, 110, 371-379.	8.2	18
168	In vivo bradykinin B2 receptor activation reduces renal fibrosis. <i>Journal of Clinical Investigation</i> , 2002, 110, 371-379.	8.2	64
169	Bradykinin B1Receptor-Mediated Changes in Renal Hemodynamics during Endotoxin-Induced Inflammation. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 1208-1215.	6.1	25
170	Homologous and heterologous induction of the human bradykinin B1-receptor and B1-receptor localisation along the rat nephron. <i>Immunopharmacology</i> , 1999, 45, 29-34.	2.0	5
171	Differential induction of functional B1-bradykinin receptors along the rat nephron in endotoxin induced inflammation. <i>Kidney International</i> , 1998, 54, 1888-1898.	5.2	33
172	B <sub>2</sub> kinin receptor upregulation by cAMP is associated with BK-induced PGE <sub>2</sub> production in rat mesangial cells. <i>American Journal of Physiology - Renal Physiology</i> , 1998, 274, F532-F540.	2.7	13
173	The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-kappaB and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts.. <i>Journal of Clinical Investigation</i> , 1998, 101, 2080-2091.	8.2	167
174	Influence of mutations of Val226 on the catalytic rate of haloalkane dehalogenase. <i>Protein Engineering, Design and Selection</i> , 1997, 10, 53-61.	2.1	23
175	Engineering Enzymes and Microorganisms for the Transformation of Synthetic Compounds. , 1997, , 47-57.		0
176	Kinetic Characterization and X-ray Structure of a Mutant of Haloalkane Dehalogenase with Higher Catalytic Activity and Modified Substrate Range. <i>Biochemistry</i> , 1996, 35, 13186-13195.	2.5	70
177	Kinetics of Halide Release of Haloalkane Dehalogenase: Evidence for a Slow Conformational Change. <i>Biochemistry</i> , 1996, 35, 5624-5632.	2.5	98
178	Specificity and Kinetics of Haloalkane Dehalogenase. <i>Journal of Biological Chemistry</i> , 1996, 271, 14747-14753.	3.4	95
179	Engineering proteins for environmental applications. <i>Current Opinion in Biotechnology</i> , 1994, 5, 253-259.	6.6	13
180	Construction of an Expression and Site-Directed Mutagenesis System of Haloalkane Dehalogenase in Escherichia coli. <i>Protein Expression and Purification</i> , 1993, 4, 479-489.	1.3	52